Author

Nikki DeAngelis

Observed names: DeAngelis, Nikki, Nikki Deangelis

Observed institutions: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Janssen Research & Development (United States)

OpenAlex ID: A5082638457

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

2021 · Jesus San-Miguel, Hervé Avet-Loiseau, et al. · Blood · 153

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

2020 · Katja Weisel, Andrew Spencer, et al. · Journal of Hematology & Oncology · 42

The High Mobility Group Box Transcription Factor Nhp6Ap Enters the Nucleus by a Calmodulin-dependent, Ran-independent Pathway

2007 · John A. Hanover, Dona C. Love, et al. · Journal of Biological Chemistry · 27

Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti–programmed cell death protein-1 (PD-1) antibody, in human cancer models

2022 · Nikki DeAngelis, Catherine Ferrante, et al. · Cancer Chemotherapy and Pharmacology · 14

Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone

2020 · Jesus F. San-Miguel, Herve Avet-Loiseau, et al. · Blood · 3

Unraveling the Dynamics of T Cell-Dependent Bispecific Antibodies in Multiple Myeloma: Multi-Omic Insights from Primary Patient Cells

2023 · Dennis J Wu, Amy S Chen, et al. · Blood

Daratumumab in transfusion‐dependent patients with low or intermediate‐ 1 risk myelodysplastic syndromes

2021 · Guillermo Garcia‐Manero, Maria Diez‐Campelo, et al. · American Journal of Hematology

Abstract 4048: GFRα1 is required for GDNF-induced viability, migration, and signaling through RET in breast cancer cells

2014 · Catherine A. Ferrante, Nikki DeAngelis, et al. · Cancer Research

Abstract B269: Effects of blocking aberrantly expressed CSF-1R in Hodgkin lymphoma.

2013 · Liam Campion, Nikki Deangelis, et al. · Molecular Cancer Therapeutics

Works count: 10

Citation count: 239

H-index: 4

I10-index: 4